PT  - JOURNAL ARTICLE
AU  - Michael Drozd
AU  - Mar Pujades-Rodriguez
AU  - Fei Sun
AU  - Kevin N Franks
AU  - Patrick J Lillie
AU  - Klaus K Witte
AU  - Mark T Kearney
AU  - Richard M Cubbon
TI  - Causes of death in people with cardiovascular disease: a prospective UK Biobank cohort study
AID  - 10.1101/2021.03.26.21254418
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.26.21254418
4099  - http://medrxiv.org/content/early/2021/03/31/2021.03.26.21254418.short
4100  - http://medrxiv.org/content/early/2021/03/31/2021.03.26.21254418.full
AB  - Cardiovascular disease (CVD) mortality has substantially improved over recent decades. Some evidence indicates this has been paralleled by an increasing proportion of non-cardiovascular mortality in people with CVD. However, the contemporary causes of death across a broad spectrum of CVDs, either alone or in combination, remains unclear.We analysed cardiovascular, infection, cancer and other causes of death prior to the COVID-19 pandemic in 493,280 participants in the prospective UK Biobank study. Studied CVDs included baseline: abdominal aortic aneurysm, atrial fibrillation, coronary artery disease, heart failure, hypertension, peripheral vascular disease, stroke, valvular heart disease and venous thromboembolic disease; we separately considered cardiovascular multimorbidity defined as the total number of these baseline CVDs. Crude mortality rates and Poisson regression analysis were used to quantify the absolute and relative risk of cause-specific death. Associations are reported as incidence rate ratios (IRR) with 95% CIs.During a median follow-up of 10.9 [IQR 10.1-11.6] years per participant, there were 27,729 deaths (20.4% primarily attributed to CVD, 53.6% to cancer, 5.0% to infection and 21.0% to other causes). As the number of co-morbid CVDs increased, the proportion of cardiovascular and infection-related deaths increased, whereas cancer and other deaths decreased. Accrual of multiple CVDs was associated with marked increases in relative risk of infection and cardiovascular death; versus those without CVD, people with three or more CVDs, the relative risk of cardiovascular death increased most (IRR 3.89; 95%CI 3.59-4.21), followed by infection (4.41; 3.44-5.64), with other (2.01; 1.72-2.35) and cancer (1.52; 1.35-1.72) being substantially less increased. All studied CVDs except atrial fibrillation were independently associated with increased risk of infection death, with heart failure (2.73; 1.60-4.66) and valvular heart disease (3.09; 2.38-4.00) posing the greatest risk.In conclusion, causes of death vary substantially between differing baseline CVDs, and according to the number of baseline CVDs, with non-cardiovascular deaths due to cancer and infection making an important contribution. Holistic and personalized care are likely to be important tools for continuing to improve outcomes in people with CVD.Competing Interest StatementMTK has received speaker fees from Merck and Novo Nordisk and unrestricted research awards from Medtronic. KKW has received speaker fees from Medtronic, Microport, Abbott, Pfizer, Bayer, and BMS. All other authors declare no competing interests.Funding StatementNo specific funding was required for this research, but some authors are or were paid by the British Heart Foundation. MD is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/18/44/33792). RMC was supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/12/80/29821). MTK is a British Heart Foundation Professor. MPR is currently employed by IQVIA, a contract research organisation. At no time did any authors, nor their institutions, receive other payment or services from a third party for any aspect of the submitted work. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank received ethical approval from the NHS Research Ethics Service (11/NW/0382); we conducted this analysis under application number 59585.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe UK Biobank dataset is available to all bona fide researchers for all types of health-related research which is in the public interest